東瑞製藥(02348.HK)附屬抗過敏藥物西可韋通過仿製藥一致性評價
格隆匯1月2日丨東瑞製藥(02348.HK)公佈,該集團附屬公司蘇州東瑞製藥有限公司的抗過敏藥物鹽酸西替利嗪片10毫克(商品名西可韋)已獲國家藥品監督管理局批准通過仿製藥質量和療效一致性評價。
鹽酸西替利嗪是一種臨牀常用的抗過敏藥物,具有選擇性拮抗組胺H1受體的作用。對症治療下述疾病的過敏性相關症狀,如季節性鼻炎、常年性過敏性鼻炎、過敏性結膜炎及過敏引起的瘙癢和蕁麻疹。該集團產品西可韋自1998年上市以來,其優良質量得到臨牀醫生和患者的高度認可。
新獲得一致性評價批件,不僅是對集團長期以來堅持質量第一的方針及產品的質量和療效的進一步認可,同時也將進一步擴大市場,加速替代原研藥進程,為患者提供優質優價的用藥選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.